Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.00, read 2026-10-23
Ethical does not pass the values gate
Price673.82 USD
Fair value655.86
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-21Read Markup696.49-3.3% to today Accumulation gives way to Markup after a 6% rise in 6 days
2026-10-15Read Accumulation658.02+2.4% to today ✓Markup gives way to Accumulation first Accumulation read since October
2026-10-11Read Markup675.00-0.2% to today Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation675.00-0.2% to today Markup gives way to Accumulation after an 8% rise in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Thermo Fisher Scientific holds its Markup at $673.82. Consolidating, no directional conviction, held for 45 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 45 days
Price at the screen
$673.82
Valuation
36.93 trailing · 25.26 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.88
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.69%
Below 33%
Interest-bearing debt is 35.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.23%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
16.99%
Below 49%
Money owed to the company is 17.0% of assets, under the 49% limit.
Pass
Revenue purity
2.23%
Below 5%
Only 2.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Thermo Fisher Scientific's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TMO's ethical verdict changes
Today TMO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Conscience Overlay
Conscience flag · AFSC Investigate
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $655.86 fair value estimate, moderate competitive moat, 10.50% revenue growth.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 5.8% above the base estimate.
Third-party analyst targets: 26 covering, consensus Strong Buy. The average target sits +5% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
High-flying Healthcare Stock, But Debt Raises Eyebrows
Imagine a global lab tech powerhouse, Thermo Fisher Scientific, equipping researchers, doctors, and scientists alike with cutting-edge tools to uncover the mysteries of life. It's a company at the forefront of healthcare diagnostics, with a revenue growth of a robust 10%. Why we pass, however, is a glaring debt ratio issue that fails our ethical screen, casting a shadow over its otherwise impressive credentials.
Despite a forward P/E of 22.8x, suggesting a premium valuation, and a matching market consensus target of $642, the underlying debt concerns are substantial enough to warrant caution. Its 15% profit margin and 14% ROE signal a healthy business, yet the ethical lapse poses a risk to long-term stability and sustainability, a critical factor in our investment thesis.
Risk sits in the form of this debt-induced ethical failing, which, while not immediately impacting the bottom line, could hold back the stock from reaching its full potential. As responsible investors, we must consider not just financial metrics but also the broader implications of corporate responsibility. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TMO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$696.49+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612.
2026-10-21Markup · changed$696.49+0.0%Entry 20
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Accumulation$696.49+0.0%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Accumulation$696.49+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$696.49+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Accumulation$696.49+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Accumulation$696.49+5.8%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markup$658.02-2.5%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markup · changed$675.00+0.0%Entry 12
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.